Phagocytes

Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology

Retrieved on: 
Thursday, July 29, 2021
University, Biotechnology, Education, Professional services, Health, Pharmaceutical, Oncology, Hospitals, Other Professional Services, Clinical trials, Finance, Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Tumor microenvironment, Macomics, the new appointments, MACOMICS, THE NEW APPOINTMENTS

Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.

Key Points: 
  • Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
  • The tumour microenvironment changes macrophage behaviour, and the company is exploiting disease specific TAM biology to selectively target these immunosuppressive cells.
  • Dr Ries joined Macomics in July 2021 and has over 20 years of immunology and drug discovery experience and is an internationally recognised expert in macrophage immunology.
  • Dr Cassetta is an author of multiple publications in high-impact international scientific journals including Cancer Cell, Nature Communications, Journal of Experimental Medicine, Blood, PNAS, Nature Reviews Drug Discovery.

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Retrieved on: 
Wednesday, June 30, 2021
Health, Stem cells, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Biology, Immunology, Immune system, Cell biology, Regulatory T cell, Phagocytes, Acute respiratory distress syndrome, Macrophage, Inflammation, MultiStem, Athersys, MULTISTEM, ATHERSYS

The publication describes the findings from extensive in vitro studies investigating the role Multipotent Adult Progenitor Cells (MAPC), clinically known as MultiStem (invimestrocel), have in modulating the inflammatory response.

Key Points: 
  • The publication describes the findings from extensive in vitro studies investigating the role Multipotent Adult Progenitor Cells (MAPC), clinically known as MultiStem (invimestrocel), have in modulating the inflammatory response.
  • Tregs are important cells in the immune system, responsible for controlling inflammation and tissue repair after injury through several mechanisms.
  • Dysregulated inflammatory responses are known to contribute to tissue and organ injury in multiple acute critical care indications, such as stroke, trauma, and acute respiratory distress syndrome (ARDS).
  • This study identifies factors secreted by MAPC and monocyte/macrophages as the primary mechanisms involved in MAPC induction of Tregs.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

Retrieved on: 
Tuesday, June 29, 2021
Branches of biology, Biology, Clusters of differentiation, Phagocytes, CD47, Cancer research, Cellular processes, Signal-regulatory protein, Immunoglobulin G, Macrophage, Phagocytosis, Signal-regulatory protein alpha

TTI-621 binds CD47, an innate immune checkpoint that binds SIRP and delivers a "dont eat me" signal to suppress macrophage phagocytosis.

Key Points: 
  • TTI-621 binds CD47, an innate immune checkpoint that binds SIRP and delivers a "dont eat me" signal to suppress macrophage phagocytosis.
  • TTI-621 is a fusion protein consisting of the CD47 binding domain of SIRP linked to the Fc region of human IgG1.
  • The dosing of this patient marks the beginning of the first Phase 1b/2 solid tumor clinical trial for Trillium, commented Dr. Ingmar Bruns, Trilliums Chief Medical Officer.
  • In this open-label Phase 1b/2 study, Trillium is adding TTI-621 to frontline doxorubicin and enrolling approximately 60 newly diagnosed LMS patients.

Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Cancer, Lung cancer, Cancer immunotherapy, Patient derived xenograft

The researchers found that early-stage lung cancer tumors coopt the immune cells, known as tissue-resident macrophages, to help invade lung tissue.

Key Points: 
  • The researchers found that early-stage lung cancer tumors coopt the immune cells, known as tissue-resident macrophages, to help invade lung tissue.
  • This process allows the tumor to hide from the immune system and proliferate into later, deadly stages of cancer.
  • In this study, scientists studied tissue samples from lung cancer tumors and surrounding lung tissue in 35 patients to see the role of macrophages in the development of the tumors.
  • Researchers identified the macrophages at play in the early development of lung cancer, identifying a potential target for future drug development.

Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Health sciences, Cell biology, Immune system, Lymphatic system, Macrophage, Phagocytes, Immunotherapy, Therapy

Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.

Key Points: 
  • Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Companys management team will participate in A.G.P.s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.
  • Investors participating in the virtual conference who are interested in meeting with members of Enlivexs management team should contact their A.G.P.
  • AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.
  • Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

Retrieved on: 
Thursday, June 10, 2021
Health, Science, Pharmaceutical, Research, Oncology, Branches of biology, Articles, Business, Cell biology, Granulocytes, Neutrophil, Phagocytes, Entrepreneurship, LYZZ Capital, Onchilles Pharma, LYZZ CAPITAL, ONCHILLES PHARMA

Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicagos Startup Investment Fund.

Key Points: 
  • Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicagos Startup Investment Fund.
  • This financing will support proof-of-concept preclinical studies as well as exploration of this novel pathway for additional drug targets.
  • The University of Chicagos Polsky Center for Entrepreneurship and Innovation manages the licensed intellectual property and negotiated the exclusive license with Onchilles Pharma.
  • Onchilles Pharma was founded on breakthrough research of a novel neutrophil pathway that when activated selectively and comprehensively kills cancer cells.

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Immunotherapy

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, 10:00 EDT.

Key Points: 
  • Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, 10:00 EDT.
  • AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.
  • Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state.
  • Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Immunotherapy

The new patent is expected to provide added intellectual property protection for pharmaceutical compositions, manufacturing methods and uses of AllocetraTM.

Key Points: 
  • The new patent is expected to provide added intellectual property protection for pharmaceutical compositions, manufacturing methods and uses of AllocetraTM.
  • Oren Hershkovitz, PhD, CEO of Enlivex, stated, We are pleased to have this patent granted in Canada, which adds to existing AllocetraTM patents in various countries around the world.
  • AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.
  • Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed toreprogram macrophages into their homeostatic state.

Why 'Killer' T Cells Could Boost COVID Immunity In Face Of New Variants

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, Infectious diseases, Lymphatic system, Phagocytes, T helper cell, Cytotoxic T cell, Virus, T cell

In particular, scientists are hopeful that T cells a group of immune cells that can target and destroy virus-infected cells could provide some immunity to COVID-19, even if antibodies become less effective at fighting the disease.

Key Points: 
  • In particular, scientists are hopeful that T cells a group of immune cells that can target and destroy virus-infected cells could provide some immunity to COVID-19, even if antibodies become less effective at fighting the disease.
  • Researchers are now picking apart the available data, looking for signs that T cells could help to maintain lasting immunity.
  • Some of these, known as killer T cells, seek out and destroy cells that are infected with the virus.
  • Others, called helper T cells are important for various immune functions, including stimulating the production of antibodies and killer T cells.

Why 'Killer' T Cells Could Boost COVID Immunity In Face Of New Variants

Retrieved on: 
Thursday, May 20, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, Infectious diseases, Lymphatic system, Phagocytes, T helper cell, Cytotoxic T cell, Virus, T cell

In particular, scientists are hopeful that T cells a group of immune cells that can target and destroy virus-infected cells could provide some immunity to COVID-19, even if antibodies become less effective at fighting the disease.

Key Points: 
  • In particular, scientists are hopeful that T cells a group of immune cells that can target and destroy virus-infected cells could provide some immunity to COVID-19, even if antibodies become less effective at fighting the disease.
  • Researchers are now picking apart the available data, looking for signs that T cells could help to maintain lasting immunity.
  • Some of these, known as killer T cells, seek out and destroy cells that are infected with the virus.
  • Others, called helper T cells are important for various immune functions, including stimulating the production of antibodies and killer T cells.